Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew B Lassman

Showing results (101-110 of 145) with videos related to

Pageof 15
Sort By:
Neuro-Oncology|February 13, 2010
A phase I trial of erlotinib in patients with nonprogressive glioblastoma multiforme postradiation therapy, and recurrent malignant gliomas and meningiomasJeffrey J Raizer, Lauren E Abrey, Andrew B Lassman, et al.
JCO Precision Oncology|September 11, 2020
Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT): A Bayesian Adaptive Platform Trial to Develop Precision Medicines for Patients With GlioblastomaBrian M Alexander, Lorenzo Trippa, Sarah Gaffey, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 6, 2016
Clinical Cancer Advances 2016: Annual Report on Progress Against Cancer From the American Society of Clinical OncologyDon S Dizon, Lada Krilov, Ezra Cohen, et al.
Neuro-Oncology|October 28, 2017
Safety, pharmacokinetics, and antitumor response of depatuxizumab mafodotin as monotherapy or in combination with temozolomide in patients with glioblastomaHui K Gan, David A Reardon, Andrew B Lassman, et al.
Neuro-Oncology|April 29, 2017
An independently validated nomogram for individualized estimation of survival among patients with newly diagnosed glioblastoma: NRG Oncology RTOG 0525 and 0825Haley Gittleman, Daniel Lim, Michael W Kattan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 17, 2010
Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working groupPatrick Y Wen, David R Macdonald, David A Reardon, et al.
Neuro-Oncology|February 13, 2010
A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapyJeffrey J Raizer, Lauren E Abrey, Andrew B Lassman, et al.
Journal of Neuro-Oncology|July 6, 2019
Epidermal growth factor receptor (EGFR) amplification rates observed in screening patients for randomized trials in glioblastomaAndrew B Lassman, Kenneth D Aldape, Peter J Ansell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 28, 2022
Infigratinib in Patients with Recurrent Gliomas and FGFR Alterations: A Multicenter Phase II StudyAndrew B Lassman, Juan Manuel Sepúlveda-Sánchez, Timothy F Cloughesy, et al.
Clinical Breast Cancer|December 18, 2021
Diagnosis of Leptomeningeal Metastasis in Women With Breast Cancer Through Identification of Tumor Cells in Cerebrospinal Fluid Using the CNSide™ AssayMargaux Wooster, Julia E McGuinness, Kathleen M Fenn, et al.
Pageof 15

Showing results (101-110 of 145) with videos related to

Sort By:
Pageof 15
Neuro-Oncology|February 13, 2010
A phase I trial of erlotinib in patients with nonprogressive glioblastoma multiforme postradiation therapy, and recurrent malignant gliomas and meningiomasJeffrey J Raizer, Lauren E Abrey, Andrew B Lassman, et al.
JCO Precision Oncology|September 11, 2020
Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT): A Bayesian Adaptive Platform Trial to Develop Precision Medicines for Patients With GlioblastomaBrian M Alexander, Lorenzo Trippa, Sarah Gaffey, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 6, 2016
Clinical Cancer Advances 2016: Annual Report on Progress Against Cancer From the American Society of Clinical OncologyDon S Dizon, Lada Krilov, Ezra Cohen, et al.
Neuro-Oncology|October 28, 2017
Safety, pharmacokinetics, and antitumor response of depatuxizumab mafodotin as monotherapy or in combination with temozolomide in patients with glioblastomaHui K Gan, David A Reardon, Andrew B Lassman, et al.
Neuro-Oncology|April 29, 2017
An independently validated nomogram for individualized estimation of survival among patients with newly diagnosed glioblastoma: NRG Oncology RTOG 0525 and 0825Haley Gittleman, Daniel Lim, Michael W Kattan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 17, 2010
Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working groupPatrick Y Wen, David R Macdonald, David A Reardon, et al.
Neuro-Oncology|February 13, 2010
A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapyJeffrey J Raizer, Lauren E Abrey, Andrew B Lassman, et al.
Journal of Neuro-Oncology|July 6, 2019
Epidermal growth factor receptor (EGFR) amplification rates observed in screening patients for randomized trials in glioblastomaAndrew B Lassman, Kenneth D Aldape, Peter J Ansell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 28, 2022
Infigratinib in Patients with Recurrent Gliomas and FGFR Alterations: A Multicenter Phase II StudyAndrew B Lassman, Juan Manuel Sepúlveda-Sánchez, Timothy F Cloughesy, et al.
Clinical Breast Cancer|December 18, 2021
Diagnosis of Leptomeningeal Metastasis in Women With Breast Cancer Through Identification of Tumor Cells in Cerebrospinal Fluid Using the CNSide™ AssayMargaux Wooster, Julia E McGuinness, Kathleen M Fenn, et al.
Pageof 15